Continuously strengthen the layout of international business, JENSCARE-B releases interim results with a gross profit of 11.827 million yuan
JENSCARE-B released its interim results for the period ending June 30, 2025, with revenue of 13.426 million yuan, gross profit of 11.827 million yuan, and R&D expenses of 88.885 million yuan. The revenue growth is mainly attributed to the commercialization progress of interventional products for treating structural heart diseases. The company has made significant progress in its product pipeline for tricuspid valve, aortic valve, and mitral valve diseases, and continues to increase its international business layout to enhance product influence and clinical application scale
According to the Zhitong Finance APP, JENSCARE-B (09877) announced its interim results for the six months ending June 30, 2025, achieving revenue of RMB 13.426 million, with no revenue recorded in the same period last year; gross profit of RMB 11.827 million, with no gross profit recorded in the same period last year; and R&D expenses of RMB 88.885 million.
The announcement stated that the revenue was mainly due to the continued commercialization of the group's interventional products for treating structural heart disease, which led to an increase in sales volume.
In the first half of 2025, the company made significant progress in its product pipeline for interventional treatments of tricuspid valve, aortic valve, and mitral valve diseases, forming a diversified and high-potential product portfolio; additionally, the company continued to strengthen its international business layout, enhancing product influence and clinical application scale, laying a solid foundation for long-term high-speed growth
